These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19189371)

  • 1. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
    Peeters M; Siena S; Van Cutsem E; Sobrero A; Hendlisz A; Cascinu S; Kalofonos H; Devercelli G; Wolf M; Amado RG
    Cancer; 2009 Apr; 115(7):1544-54. PubMed ID: 19189371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
    Amado RG; Wolf M; Peeters M; Van Cutsem E; Siena S; Freeman DJ; Juan T; Sikorski R; Suggs S; Radinsky R; Patterson SD; Chang DD
    J Clin Oncol; 2008 Apr; 26(10):1626-34. PubMed ID: 18316791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
    Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
    J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
    Kim TW; Elme A; Kusic Z; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Bilic A; Manojlovic N; Dong J; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
    Br J Cancer; 2016 Nov; 115(10):1206-1214. PubMed ID: 27736842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
    Thaler J; Karthaus M; Mineur L; Greil R; Letocha H; Hofheinz R; Fernebro E; Gamelin E; Baños A; Köhne CH
    BMC Cancer; 2012 Sep; 12():438. PubMed ID: 23020584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
    Weber J; McCormack PL
    BioDrugs; 2008; 22(6):403-11. PubMed ID: 18998757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.
    Wang J; Zhao Z; Barber B; Sherrill B; Peeters M; Wiezorek J
    Br J Cancer; 2011 Jun; 104(12):1848-53. PubMed ID: 21610704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on panitumumab in metastatic colorectal cancer.
    Keating GM
    BioDrugs; 2010 Aug; 24(4):275-8. PubMed ID: 20623992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Panitumumab-treatment of metastatic colorectal cancer].
    Pikó B
    Magy Onkol; 2009 Jun; 53(2):135-42. PubMed ID: 19581179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab.
    Odom D; Barber B; Bennett L; Peeters M; Zhao Z; Kaye J; Wolf M; Wiezorek J
    Int J Colorectal Dis; 2011 Feb; 26(2):173-81. PubMed ID: 21190026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panitumumab: a review of its use in metastatic colorectal cancer.
    Keating GM
    Drugs; 2010 May; 70(8):1059-78. PubMed ID: 20481659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA drug approval summary: panitumumab (Vectibix).
    Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of panitumumab into the treatment of colorectal cancer.
    Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
    Au HJ; Karapetis CS; O'Callaghan CJ; Tu D; Moore MJ; Zalcberg JR; Kennecke H; Shapiro JD; Koski S; Pavlakis N; Charpentier D; Wyld D; Jefford M; Knight GJ; Magoski NM; Brundage MD; Jonker DJ
    J Clin Oncol; 2009 Apr; 27(11):1822-8. PubMed ID: 19273701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.
    Peeters M; Oliner KS; Parker A; Siena S; Van Cutsem E; Huang J; Humblet Y; Van Laethem JL; André T; Wiezorek J; Reese D; Patterson SD
    Clin Cancer Res; 2013 Apr; 19(7):1902-12. PubMed ID: 23325582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.
    Poulin-Costello M; Azoulay L; Van Cutsem E; Peeters M; Siena S; Wolf M
    Target Oncol; 2013 Jun; 8(2):127-36. PubMed ID: 23625191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer.
    Hecht JR; Mitchell E; Neubauer MA; Burris HA; Swanson P; Lopez T; Buchanan G; Reiner M; Gansert J; Berlin J
    Clin Cancer Res; 2010 Apr; 16(7):2205-13. PubMed ID: 20332321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
    Siena S; Peeters M; Van Cutsem E; Humblet Y; Conte P; Bajetta E; Comandini D; Bodoky G; Van Hazel G; Salek T; Wolf M; Devercelli G; Woolley M; Amado RG
    Br J Cancer; 2007 Dec; 97(11):1469-74. PubMed ID: 18040272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-treatment markers as predictors to guide anti-EGFR MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis.
    Hu J; Zhang Z; Zheng R; Cheng L; Yang M; Li L; Liu B; Qian X
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):275-285. PubMed ID: 27878357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.